QQ客服 官方微博 反馈留言

	Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
	Li, Caina; Yang, Miaomiao; Wang, Xiaofeng; Zhang, Hua; Yao, Chenjiang; Sun, Sujuan; Liu, Quan; Pan, Hao; Liu, Shuainan; Huan, Yi
	2018
卷号	150页码:46-53
关键词	Diabetes Long-acting GLP-1 analog Glutazumab Glucose metabolism beta-Cell function
ISSN号	0006-2952
DOI	10.1016/j.bcp.2018.01.029
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6361077
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li, Caina,Yang, Miaomiao,Wang, Xiaofeng,et al. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites[J],2018,150:46-53.
APA	Li, Caina.,Yang, Miaomiao.,Wang, Xiaofeng.,Zhang, Hua.,Yao, Chenjiang.,...&Shen, Zhufang.(2018).Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.,150,46-53.
MLA	Li, Caina,et al."Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites".150(2018):46-53.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。